Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements By Ogkologos - June 11, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FIGHT-302 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL MOST POPULAR Time to take on 9 new Cancer Grand Challenges March 8, 2023 New independent tobacco review sets roadmap for a smokefree England for... June 9, 2022 The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr.... July 16, 2018 A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with... January 16, 2026 Load more HOT NEWS From smart knives to virtual reality tumours: five innovations in understanding... FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients... A Nurse’s Love For Oncology Patients Coronavirus reports – Part 8: “Going into hospital during this time...
